CN107091931A - 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途 - Google Patents

抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途 Download PDF

Info

Publication number
CN107091931A
CN107091931A CN201710252366.1A CN201710252366A CN107091931A CN 107091931 A CN107091931 A CN 107091931A CN 201710252366 A CN201710252366 A CN 201710252366A CN 107091931 A CN107091931 A CN 107091931A
Authority
CN
China
Prior art keywords
nucleoprotein
antibody
common
altogether
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710252366.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·魏霍芬
T·恩格贝尔
J·格林姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biological Neuroscience International Co
Original Assignee
Biological Neuroscience International Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological Neuroscience International Co filed Critical Biological Neuroscience International Co
Publication of CN107091931A publication Critical patent/CN107091931A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201710252366.1A 2011-11-02 2012-10-29 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途 Pending CN107091931A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
US61/554,924 2011-11-02
CN201280065165.6A CN104040342A (zh) 2011-11-02 2012-10-29 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280065165.6A Division CN104040342A (zh) 2011-11-02 2012-10-29 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途

Publications (1)

Publication Number Publication Date
CN107091931A true CN107091931A (zh) 2017-08-25

Family

ID=48192661

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710252366.1A Pending CN107091931A (zh) 2011-11-02 2012-10-29 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途
CN201280065165.6A Pending CN104040342A (zh) 2011-11-02 2012-10-29 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280065165.6A Pending CN104040342A (zh) 2011-11-02 2012-10-29 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途

Country Status (13)

Country Link
US (3) US20140295465A1 (https=)
EP (1) EP2773957B1 (https=)
JP (1) JP6263473B2 (https=)
KR (1) KR102036938B1 (https=)
CN (2) CN107091931A (https=)
AU (1) AU2012332814B2 (https=)
BR (1) BR112014010664A2 (https=)
CA (1) CA2854131C (https=)
EA (1) EA034213B1 (https=)
IL (1) IL232373B (https=)
MX (1) MX356797B (https=)
WO (1) WO2013066818A1 (https=)
ZA (1) ZA201403879B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111175484A (zh) * 2018-09-26 2020-05-19 欧蒙医学实验诊断股份公司 神经自身免疫性疾病的诊断

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
CA3049110A1 (en) * 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α－共核蛋白疾病的方法
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
CN101692092A (zh) * 2009-09-24 2010-04-07 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α－共核蛋白疾病的方法
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
CN101692092A (zh) * 2009-09-24 2010-04-07 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMMANOUILIDOU,E等: "Cell-Produced alpha-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival", 《JOURNAL OF NEUROSCIENCE》 *
陈敏等: "帕金森病与α-共核蛋白的相关研究进展", 《中国康复》 *
黄银霞等: "帕金森病相关蛋白α-共核蛋白的可溶性表达、纯化及抗体制备", 《中国老年学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111175484A (zh) * 2018-09-26 2020-05-19 欧蒙医学实验诊断股份公司 神经自身免疫性疾病的诊断
CN111175484B (zh) * 2018-09-26 2024-04-16 欧蒙医学实验诊断股份公司 神经自身免疫性疾病的诊断

Also Published As

Publication number Publication date
JP2014533357A (ja) 2014-12-11
EA034213B1 (ru) 2020-01-17
AU2012332814B2 (en) 2017-12-14
HK1201585A1 (en) 2015-09-04
MX2014005378A (es) 2015-01-19
MX356797B (es) 2018-06-14
US20180011112A1 (en) 2018-01-11
EP2773957A1 (en) 2014-09-10
CN104040342A (zh) 2014-09-10
US20140295465A1 (en) 2014-10-02
EP2773957A4 (en) 2015-06-24
KR20140095074A (ko) 2014-07-31
BR112014010664A2 (pt) 2017-04-25
CA2854131A1 (en) 2013-05-10
ZA201403879B (en) 2018-11-28
IL232373B (en) 2018-08-30
US20190094245A1 (en) 2019-03-28
CA2854131C (en) 2020-07-07
KR102036938B1 (ko) 2019-10-25
EP2773957B1 (en) 2017-11-29
IL232373A0 (en) 2014-06-30
AU2012332814A1 (en) 2014-06-12
NZ625217A (en) 2016-07-29
WO2013066818A1 (en) 2013-05-10
JP6263473B2 (ja) 2018-01-31
EA201490883A1 (ru) 2014-10-30

Similar Documents

Publication Publication Date Title
CN107091931A (zh) 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途
US9216217B2 (en) Oligomer-specific amyloid beta epitope and antibodies
ES2773961T3 (es) Uso de moléculas de unión a semaforina-4D para el tratamiento de trastornos neurodegenerativos
ES2821814T3 (es) Uso de moléculas de unión a semaforina-4D para el tratamiento de la aterosclerosis
KR20210126045A (ko) 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여
JP2024503724A (ja) 免疫調節抗体およびその使用
AU2013205000B2 (en) Oligomer-specific amyloid beta epitope and antibodies
HK1231887A1 (en) Oligomer-specific amyloid beta epitope and antibodies
HK1185350B (en) Oligomer-specific amyloid beta epitope and antibodies
HK1201585B (en) Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
KR20260046520A (ko) 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여
NZ625217B2 (en) Use of an anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170825